Johnson & Johnson receives positive CHMP opinion recommending full approval for SIRTURO® (bedaquiline) for treatment of multidrug-resistant TB

-- CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation

-- Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies

Read the full press release here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Johnson & Johnson

Published: April 29, 2024, 8:54 p.m.

Last updated: May 7, 2024, 7:56 p.m.

Print Share